To date, two cytokines have achieved FDA approval as single agents for cancer treatment: high-dose, bolus IL-2 for metastatic melanoma and renal cell carcinoma and IFN-α for the adjuvant therapy of Stage III melanoma. This evidence concerns the gene IFNA1 and renal cell carcinoma.